iCAD, an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced that it has completed the acquisition of the VuCOMP cancer detection portfolio, including the M-Vu® computer aided detection (CAD) technology platform.

In April 2015, iCAD acquired VuCOMP’s M-Vu® Breast Density software product.

VuCOMP, Inc. is a leading provider of advanced computer applications used in the detection of breast cancer. The acquisition includes an extensive library of related clinical data with important implications on future cancer detection research and patents, as well as VuCOMP’s key personnel and existing customer base.

"This acquisition strongly complements iCAD’s strategy and will help accelerate our efforts to bring new and innovative cancer detection and workflow solutions to market, particularly as we prepare to launch our tomosynthesis cancer detection solutions," said Ken Ferry, CEO of iCAD.

"The addition of VuCOMP’s leading researchers and engineers to the iCAD team also represents an important resource for our deep learning technology initiatives aimed at creating improved solutions to help healthcare providers detect cancer early and positions us to maintain and expand our leadership position in the industry in the years ahead."

With this acquisition, iCAD will provide ongoing support services to VuCOMP M-Vu® customers. iCAD will also provide opportunities for customers to leverage the additional value-add solutions and services offered by the company.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers.

iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue.

The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer.